Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computer Simulation | 14 | 2019 | 645 | 2.290 |
Why?
|
| Software | 14 | 2019 | 677 | 2.280 |
Why?
|
| Models, Genetic | 9 | 2014 | 759 | 1.300 |
Why?
|
| Limonins | 1 | 2024 | 2 | 0.950 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 119 | 0.890 |
Why?
|
| Mouth Neoplasms | 1 | 2024 | 82 | 0.880 |
Why?
|
| Computational Biology | 5 | 2019 | 810 | 0.870 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 723 | 0.820 |
Why?
|
| Workflow | 2 | 2019 | 117 | 0.750 |
Why?
|
| Apoptosis | 2 | 2024 | 1777 | 0.710 |
Why?
|
| Genetic Variation | 6 | 2014 | 1492 | 0.690 |
Why?
|
| Programming Languages | 2 | 2018 | 19 | 0.690 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 248 | 0.680 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 662 | 0.650 |
Why?
|
| Genome, Human | 9 | 2015 | 1258 | 0.590 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 1651 | 0.580 |
Why?
|
| Genome-Wide Association Study | 9 | 2015 | 1680 | 0.520 |
Why?
|
| Biological Evolution | 4 | 2012 | 225 | 0.460 |
Why?
|
| Disease | 4 | 2014 | 129 | 0.460 |
Why?
|
| Alleles | 5 | 2015 | 1615 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 555 | 0.410 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2284 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2015 | 2625 | 0.340 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3328 | 0.320 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2016 | 859 | 0.310 |
Why?
|
| Genetics, Population | 2 | 2010 | 187 | 0.310 |
Why?
|
| Algorithms | 3 | 2011 | 1605 | 0.310 |
Why?
|
| User-Computer Interface | 3 | 2019 | 151 | 0.290 |
Why?
|
| Cell Cycle | 2 | 2023 | 608 | 0.260 |
Why?
|
| Internet | 3 | 2018 | 375 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 237 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 1746 | 0.250 |
Why?
|
| Mice, Inbred NOD | 2 | 2023 | 283 | 0.250 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2024 | 49 | 0.230 |
Why?
|
| Mice, SCID | 2 | 2023 | 565 | 0.230 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 431 | 0.220 |
Why?
|
| Models, Statistical | 4 | 2014 | 471 | 0.220 |
Why?
|
| Molecular Sequence Annotation | 2 | 2015 | 148 | 0.210 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2023 | 16 | 0.210 |
Why?
|
| Humans | 32 | 2024 | 124020 | 0.200 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 776 | 0.200 |
Why?
|
| Signal Transduction | 5 | 2024 | 4498 | 0.200 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 482 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2863 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2017 | 3146 | 0.180 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2020 | 7 | 0.170 |
Why?
|
| Histone Deacetylase 6 | 1 | 2019 | 7 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 371 | 0.170 |
Why?
|
| Hyperalgesia | 1 | 2019 | 25 | 0.170 |
Why?
|
| Neuralgia | 1 | 2020 | 44 | 0.160 |
Why?
|
| Epidermis | 1 | 2019 | 60 | 0.160 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2019 | 9 | 0.160 |
Why?
|
| Computing Methodologies | 1 | 2019 | 1 | 0.160 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 11 | 0.160 |
Why?
|
| Isotope Labeling | 1 | 2019 | 104 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 116 | 0.160 |
Why?
|
| Stomatitis, Aphthous | 1 | 2018 | 3 | 0.150 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 49 | 0.150 |
Why?
|
| Cisplatin | 1 | 2019 | 234 | 0.150 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 672 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 329 | 0.140 |
Why?
|
| Dermatomyositis | 2 | 2015 | 21 | 0.140 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2017 | 48 | 0.140 |
Why?
|
| Ureteral Neoplasms | 1 | 2017 | 25 | 0.140 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2017 | 35 | 0.140 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 77 | 0.140 |
Why?
|
| Research | 1 | 2019 | 263 | 0.140 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 44 | 0.140 |
Why?
|
| Urothelium | 1 | 2017 | 60 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 564 | 0.140 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2016 | 3 | 0.140 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 153 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 175 | 0.130 |
Why?
|
| Paracrine Communication | 1 | 2016 | 68 | 0.130 |
Why?
|
| Multigene Family | 1 | 2017 | 297 | 0.130 |
Why?
|
| Genotype | 4 | 2014 | 2552 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 352 | 0.130 |
Why?
|
| Ureter | 1 | 2017 | 97 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2014 | 720 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 256 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2020 | 876 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 282 | 0.120 |
Why?
|
| Myositis | 1 | 2015 | 62 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 286 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 5798 | 0.120 |
Why?
|
| Genomics | 3 | 2017 | 1484 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 419 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 296 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2015 | 243 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1474 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 540 | 0.110 |
Why?
|
| Quality Control | 1 | 2014 | 119 | 0.110 |
Why?
|
| Virus Integration | 1 | 2014 | 41 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 103 | 0.110 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 332 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 460 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 124 | 0.100 |
Why?
|
| Mice | 4 | 2023 | 17581 | 0.100 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 309 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2014 | 332 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 328 | 0.100 |
Why?
|
| Animals | 6 | 2023 | 34000 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2014 | 695 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 353 | 0.090 |
Why?
|
| Fertility | 1 | 2013 | 257 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 426 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 251 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1111 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 481 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 187 | 0.090 |
Why?
|
| DNA Copy Number Variations | 2 | 2017 | 942 | 0.090 |
Why?
|
| Chromatin | 1 | 2014 | 553 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1888 | 0.090 |
Why?
|
| Ganglia, Spinal | 2 | 2020 | 69 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 231 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3269 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2010 | 604 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 800 | 0.080 |
Why?
|
| Cell Movement | 2 | 2023 | 831 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1554 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2814 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2014 | 833 | 0.070 |
Why?
|
| Neoplasms | 2 | 2018 | 2760 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 81 | 0.070 |
Why?
|
| Aged | 7 | 2019 | 19520 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 3087 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2006 | 155 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 238 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 260 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2009 | 792 | 0.060 |
Why?
|
| Computer Graphics | 1 | 2005 | 38 | 0.060 |
Why?
|
| Diploidy | 1 | 2005 | 35 | 0.060 |
Why?
|
| Genetics | 1 | 2005 | 24 | 0.060 |
Why?
|
| Time | 1 | 2005 | 93 | 0.060 |
Why?
|
| Middle Aged | 7 | 2019 | 26572 | 0.060 |
Why?
|
| Female | 11 | 2019 | 66198 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2004 | 126 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 356 | 0.050 |
Why?
|
| Male | 9 | 2019 | 60919 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 290 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2017 | 398 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 329 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2256 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2023 | 140 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 418 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3717 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 214 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 1589 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 1697 | 0.040 |
Why?
|
| Proteomics | 1 | 2004 | 496 | 0.040 |
Why?
|
| Meninges | 1 | 2020 | 18 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2020 | 56 | 0.040 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2020 | 37 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1454 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2019 | 73 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4333 | 0.040 |
Why?
|
| Isotopes | 1 | 2019 | 27 | 0.040 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2018 | 5 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 254 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 204 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 19 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 265 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 777 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 195 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 122 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 137 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 29292 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 49 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1207 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 66 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6460 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 202 | 0.030 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 520 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 95 | 0.030 |
Why?
|
| Phenotype | 2 | 2017 | 4242 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2019 | 426 | 0.030 |
Why?
|
| Cloud Computing | 1 | 2015 | 11 | 0.030 |
Why?
|
| Polymyositis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 131 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 788 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 6279 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 299 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 865 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 472 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 479 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1421 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 222 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 155 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 669 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 210 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 86 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 514 | 0.030 |
Why?
|
| Adolescent | 3 | 2018 | 19224 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 3427 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1172 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 95 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 138 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2037 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 944 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 322 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1015 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10242 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 434 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2496 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1879 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1957 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 143 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3581 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 257 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4607 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 4388 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12267 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 63 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2005 | 112 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 687 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 154 | 0.010 |
Why?
|
| Melanoma | 1 | 2011 | 835 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 8971 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 64 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 124 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 230 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 723 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 294 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 354 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 16242 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1490 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 1233 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2086 | 0.010 |
Why?
|